2026-2030年全球性行為感染（STI）治療市場

全球性行為感染傳染病（STI）治療市場預計將在 2025 年至 2030 年間成長至 268.55 億美元，預測期內複合年成長率為 7.2%。

本報告對全球性行為感染(STI) 治療市場進行了全面分析，包括市場規模和預測、趨勢、成長要素、挑戰以及對約 25 家公司的供應商分析。

本報告對當前市場狀況、最新趨勢和促進因素以及整體市場環境進行了最新分析。推動市場成長的因素包括分子診斷和就地檢驗技術的進步、長效注射療法和新型抗病毒藥物的推廣應用、公眾健康意識的提高以及政府主導的預防措施。

本研究客觀地結合了一手和二手訊息，包括主要行業相關人員的意見。報告內容涵蓋主要公司分析、全面的市場規模數據、區域細分分析以及供應商格局。報告還包含歷史數據和預測數據。

本研究指出，未來幾年，新一代疫苗和免疫療法的研發將是全球性行為感染（STI）治療市場成長的主要驅動力之一。此外，針對抗菌藥物抗藥性（AMR）策略的出現、聯合治療的推廣應用，以及整合式遠端醫療生態系統和數位處方平台的興起，預計也將帶來顯著的市場需求。

目錄

第1章執行摘要

第2章 Technavio 分析

• 分析定價、生命週期、顧客購買籃子、採用率和購買標準。
• 輸入的重要性及差異化因素
• 干擾因素
• 促進因素和挑戰的影響

第3章 市場狀況

• 市場生態系統
• 市場特徵
• 價值鏈分析

第4章 市場規模

• 市場的定義
• 市場區隔分析
• 2025年市場規模
• 市場展望，2025-2030年

第5章 市場規模與表現

• 2020-2024年全球性行為感染傳染病（STD）治療市場
• 按類型分類的細分市場分析，2020-2024 年
• 按給藥途徑分類的細分市場分析，2020-2024 年
• 2020-2024 年最終用戶細分市場分析
• 區域區隔市場分析，2020-2024 年
• 2020-2024年各國細分市場分析

第6章 定性分析

• 人工智慧的影響：全球性行為感染傳染病（STD）治療市場
• 地緣政治衝突對全球性行為感染（STI）治療市場的影響。

第7章：五力分析

第8章 市場區隔：依類型

• 比較：按類型
• 病毒感染疾病
• 細菌感染疾病
• 其他
• 市場機會：按類型分類

第9章 市場區隔：依給藥途徑

• 比較：按給藥途徑
• 口服
• 外用
• 注射藥物
• 市場機會：依給藥途徑分類

第10章 市場區隔：依最終用戶分類

• 比較：按最終用戶
• 醫院和診所
• 診斷中心
• 個人
• 市場機會：依最終用戶分類

第11章 客戶情況

第12章 區域情勢

• 區域分類
• 區域比較
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
• 亞洲
  • 中國
  • 印度
  • 日本
  • 韓國
  • 印尼
  • 泰國
• 世界其他地區（RoW）
  • 巴西
  • 沙烏地阿拉伯
  • UAE
  • 土耳其
  • 阿根廷
  • 哥倫比亞
  • 南非
  • 以色列
• 市場機會：按地區分類

第13章 促進因素、挑戰與機遇

• 市場促進因素
• 市場挑戰
• 促進因素和挑戰的影響
• 市場機遇

第14章 競爭格局

• 概述
• 競爭格局
• 混亂局面
• 產業風險

第15章 競爭分析

• 公司簡介
• 公司排名指標
• 企業市場定位
• AbbVie Inc.
• Aurobindo Pharma Ltd.
• Cipla Inc.
• Dr. Reddys Laboratories Ltd.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Hikma Pharmaceuticals Plc
• Johnson and Johnson Services
• Merck and Co. Inc.
• Pfizer Inc.
• Sandoz Group AG
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Ltd.
• Viatris Inc.

第16章附錄

The global sexually transmitted diseases (STD) treatment market is forecasted to grow by USD 26805.5 mn during 2025-2030, accelerating at a CAGR of 7.2% during the forecast period. The report on the global sexually transmitted diseases (STD) treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by technological advancements in molecular diagnostics and point-of-care testing, expansion of long-acting injectable therapies and novel antiviral formulations, increasing public health awareness and government-led preventive initiatives.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global sexually transmitted diseases (STD) treatment market is segmented as below:

By Type

• Viral infections
• Bacterial infections
• Others

By Route Of Administration

• Oral
• Topical
• Injectable

By End-User

• Hospital and clinics
• Diagnostic centers
• Individuals

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the development of next-generation vaccines and immunotherapeutic interventions as one of the prime reasons driving the global sexually transmitted diseases (STD) treatment market growth during the next few years. Also, emergence of targeted antimicrobial resistance (AMR) solutions and combination therapies and rise of integrated telehealth ecosystems and digital prescription platforms will lead to sizable demand in the market.

The report on the global sexually transmitted diseases (STD) treatment market covers the following areas:

• Global sexually transmitted diseases (STD) treatment market sizing
• Global sexually transmitted diseases (STD) treatment market forecast
• Global sexually transmitted diseases (STD) treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global sexually transmitted diseases (STD) treatment market vendors that include AbbVie Inc., Aurobindo Pharma Ltd., Bavarian Nordic AS, Bristol Myers Squibb Co., Cipla Inc., Dr. Reddys Laboratories Ltd., Evofem Biosciences Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Inovio Pharmaceuticals Inc., Johnson and Johnson Services, Merck and Co. Inc., Pfizer Inc., Sandoz Group AG, Sanofi SA, Sun Pharmaceutical Industries, Teva Pharmaceutical Ltd., Viatris Inc.. Also, the global sexually transmitted diseases (STD) treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by Route of Administration
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Sexually Transmitted Diseases (STD) Treatment Market 2020 - 2024
  • Historic Market Size - Data Table on Global Sexually Transmitted Diseases (STD) Treatment Market 2020 - 2024 ($ million)
• 5.2 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
• 5.3 Route of Administration segment analysis 2020 - 2024
  • Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
• 5.4 End-user segment analysis 2020 - 2024
  • Historic Market Size - End-user Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on global sexually transmitted diseases (STD) treatment market
• 6.2 Impact of geopolitical conflicts on global sexually transmitted diseases (STD) treatment market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Type

• 8.1 Market segments
• 8.2 Comparison by Type
• 8.3 Viral infections - Market size and forecast 2025-2030
• 8.4 Bacterial infections - Market size and forecast 2025-2030
• 8.5 Others - Market size and forecast 2025-2030
• 8.6 Market opportunity by Type
  • Market opportunity by Type ($ million)

9 Market Segmentation by Route of Administration

• 9.1 Market segments
• 9.2 Comparison by Route of Administration
• 9.3 Oral - Market size and forecast 2025-2030
• 9.4 Topical - Market size and forecast 2025-2030
• 9.5 Injectable - Market size and forecast 2025-2030
• 9.6 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ million)

10 Market Segmentation by End-user

• 10.1 Market segments
• 10.2 Comparison by End-user
• 10.3 Hospital and clinics - Market size and forecast 2025-2030
• 10.4 Diagnostic centers - Market size and forecast 2025-2030
• 10.5 Individuals - Market size and forecast 2025-2030
• 10.6 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 India - Market size and forecast 2025-2030
  • 12.5.3 Japan - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Turkey - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 Colombia - Market size and forecast 2025-2030
  • 12.6.7 South Africa - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Technological advancements in molecular diagnostics and point-of-care testing
  • Expansion of long-acting injectable therapies and novel antiviral formulations
  • Increasing public health awareness and government-led preventive initiatives
• 13.2 Market challenges
  • Escalation of multidrug-resistant pathogens and limitation of pharmaceutical pipelines
  • Pervasive social stigma and its impact on screening and treatment adherence
  • Significant health disparities and inequitable access to specialized diagnostic infrastructure
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Development of next-generation vaccines and immunotherapeutic interventions
  • Emergence of targeted antimicrobial resistance (AMR) solutions and combination therapies
  • Rise of integrated telehealth ecosystems and digital prescription platforms

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 AbbVie Inc.
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Business segments
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • AbbVie Inc. - Segment focus
  • SWOT
• 15.5 Aurobindo Pharma Ltd.
  • Aurobindo Pharma Ltd. - Overview
  • Aurobindo Pharma Ltd. - Business segments
  • Aurobindo Pharma Ltd. - Key news
  • Aurobindo Pharma Ltd. - Key offerings
  • Aurobindo Pharma Ltd. - Segment focus
  • SWOT
• 15.6 Cipla Inc.
  • Cipla Inc. - Overview
  • Cipla Inc. - Business segments
  • Cipla Inc. - Key news
  • Cipla Inc. - Key offerings
  • Cipla Inc. - Segment focus
  • SWOT
• 15.7 Dr. Reddys Laboratories Ltd.
  • Dr. Reddys Laboratories Ltd. - Overview
  • Dr. Reddys Laboratories Ltd. - Business segments
  • Dr. Reddys Laboratories Ltd. - Key news
  • Dr. Reddys Laboratories Ltd. - Key offerings
  • Dr. Reddys Laboratories Ltd. - Segment focus
  • SWOT
• 15.8 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 15.9 Gilead Sciences Inc.
  • Gilead Sciences Inc. - Overview
  • Gilead Sciences Inc. - Business segments
  • Gilead Sciences Inc. - Key offerings
  • Gilead Sciences Inc. - Segment focus
  • SWOT
• 15.10 GlaxoSmithKline Plc
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key news
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Segment focus
  • SWOT
• 15.11 Hikma Pharmaceuticals Plc
  • Hikma Pharmaceuticals Plc - Overview
  • Hikma Pharmaceuticals Plc - Business segments
  • Hikma Pharmaceuticals Plc - Key news
  • Hikma Pharmaceuticals Plc - Key offerings
  • Hikma Pharmaceuticals Plc - Segment focus
  • SWOT
• 15.12 Johnson and Johnson Services
  • Johnson and Johnson Services - Overview
  • Johnson and Johnson Services - Business segments
  • Johnson and Johnson Services - Key news
  • Johnson and Johnson Services - Key offerings
  • Johnson and Johnson Services - Segment focus
  • SWOT
• 15.13 Merck and Co. Inc.
  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Business segments
  • Merck and Co. Inc. - Key news
  • Merck and Co. Inc. - Key offerings
  • Merck and Co. Inc. - Segment focus
  • SWOT
• 15.14 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.15 Sandoz Group AG
  • Sandoz Group AG - Overview
  • Sandoz Group AG - Business segments
  • Sandoz Group AG - Key news
  • Sandoz Group AG - Key offerings
  • Sandoz Group AG - Segment focus
  • SWOT
• 15.16 Sun Pharmaceutical Industries
  • Sun Pharmaceutical Industries - Overview
  • Sun Pharmaceutical Industries - Business segments
  • Sun Pharmaceutical Industries - Key news
  • Sun Pharmaceutical Industries - Key offerings
  • Sun Pharmaceutical Industries - Segment focus
  • SWOT
• 15.17 Teva Pharmaceutical Ltd.
  • Teva Pharmaceutical Ltd. - Overview
  • Teva Pharmaceutical Ltd. - Business segments
  • Teva Pharmaceutical Ltd. - Key news
  • Teva Pharmaceutical Ltd. - Key offerings
  • Teva Pharmaceutical Ltd. - Segment focus
  • SWOT
• 15.18 Viatris Inc.
  • Viatris Inc. - Overview
  • Viatris Inc. - Business segments
  • Viatris Inc. - Key news
  • Viatris Inc. - Key offerings
  • Viatris Inc. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations